Latest Transformation News

Syntara Limited has initiated dosing in its Phase 1a/b trial for SNT-9465, a topical drug targeting hypertrophic scars, aiming to offer a non-invasive alternative to current treatments. Results expected in early 2026 could pave the way for global development and FDA approval.

Paradigm Biopharmaceuticals has advanced its global Phase 3 trial for knee osteoarthritis pain with active patient recruitment in Australia and the US, backed by a $41.2 million convertible note facility. The company also expanded its osteoarthritis portfolio through the acquisition of Proteobioactives and the Pentacoxib™ oral therapy.

Iltani Resources has delivered robust drilling results at its Orient Silver-Indium Project, reinforcing its status as a leading silver-indium discovery in Australia, while securing nearly $3 million to advance exploration.

Urbanise.com Limited reported a 4.2% revenue increase for FY2025, driven by a landmark partnership and equity investment from National Australia Bank. The company achieved positive operating cash flow for the fourth consecutive quarter, setting the stage for its next growth phase.

TALi Digital has acquired the You Can Do It! education program, boosting its social-emotional learning portfolio, while raising $0.8 million through a private placement to support growth initiatives.

Greatland Resources has completed a landmark FY25, integrating Telfer and Havieron operations, producing nearly 200,000 ounces of gold, and raising $490 million in a successful ASX IPO. The company sets ambitious FY26 targets focused on extending Telfer’s mine life through its largest drilling program ever.

Biome Australia Limited has delivered record sales revenue in Q4 FY25 alongside positive EBITDA, setting the stage for its first full-year net profit. Strategic product launches and international expansion underpin its strong growth trajectory.

LTR Pharma has initiated commercial distribution of its nasal spray SPONTAN through Australia's Symbion pharmacy network and is advancing ROXUS development for a US launch in early 2026, while expanding its pipeline with a new intranasal treatment for swallowing disorders.

Algorae Pharmaceuticals has advanced its AI-driven drug discovery platform into preclinical validation through a strategic collaboration with the Peter MacCallum Cancer Centre, while progressing its therapeutic pipeline and commercial leadership.

EMVision Medical Devices has secured ethics approvals for two pivotal clinical studies and received a $400,000 milestone payment, marking significant progress toward commercialising its portable First Responder brain scanner.

Powerhouse Ventures Limited reports its first operating cash profit within a year of restructuring, driven by three distinct business divisions and a strengthened balance sheet.

Emyria has inked a pivotal agreement with Avive Health to launch its first Empax clinic in Queensland, expanding its innovative mental health treatment network. This move builds on its recent Medibank partnership, advancing accessible, reimbursed care for treatment-resistant conditions.